Grail's $950 blood test isn't FDA-approved yet, but you can get one easily via telemedicine.
Zoë Meyers for BI
Is a $950 test that searches for upwards of 50 types of cancer in your bloodstream worth it? That depends on who you ask.Grail, the Silicon Valley healthcare company developing blood tests to pick up early cancer, presented its largest study to date on Saturday at the American Society of Clinical Oncology meeting (ASCO) in Chicago.The study, tracking more than 140,000 older people in the UK, assessed whether people who took Grail's $950 Galleri test each year for three years could catch cancer before it hit the later stages (Stage 3 and Stage 4).The study was unsuccessful at its stated goal of meaningfully curbing more late-stage cancers. Still, the company says these results are a clear signal that their test is working."When you add Galleri to single cancer, standard-of-care screening, we found four times more cancer in the population," Grail President and incoming CEO Joshua Ofman told Business Insider, shortly before the results were released.
The Galleri blood test looks for tell-tale signs of cancer DNA in your blood.
Zoë Meyers for BI
